

## Special Issue

# The Present and Future of Allergen Immunotherapy in Personalized Medicine

### Message from the Guest Editor

Allergen immunotherapy is a medical treatment for allergies. It is a *disease-modifying therapy*, indicated for the treatment of allergic rhinitis, allergic conjunctivitis, allergic asthma, and Hymenoptera hypersensitivity.

Allergen immunotherapy can be administered either subcutaneously in a physician's office or sublingually by a patient at home. Oral immunotherapy is used in food allergies. In addition, several biologics that control specific responsible molecules and directly suppress allergic reactions have recently become available. Even in the current era, the significance of allergen immunotherapy, which modifies the natural history of allergic diseases, seems to be prominent. This Special Issue aims to highlight the role of personalized medicine in clinical practice, providing a complete overview of allergen immunotherapy and highlighting the critical issues in its management. We welcome the submission of original papers and reviews regarding allergen immunotherapy for allergic diseases.

### Guest Editor

Prof. Dr. Giorgio Walter Canonica

1. Personalized Medicine, Asthma and Allergy-IRCCS Humanitas Research Hospital-Via Alessandro Manzoni, 56, 20089 Rozzano, Italy
2. Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy

### Deadline for manuscript submissions

closed (15 June 2023)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/110569](https://mdpi.com/si/110569)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).